This is the PDF eBook version for Fc Receptors by Marc Daeron, Falk Nimmerjahn
Table of Contents
Part I: Old and new FcRs
Hiromi Kubagawa, Yoshiki Kubagawa, Dewitt Jones, Tahseen H. Nasti, Mark Walter, and Kazuhito Honjo
The Old but New IgM Fc Receptor (FcµR)
F.J. Li, W.J. Won, E.J. Becker Jr., J.L. Easlick, E. Tabengwa, R. Li, M. Shakhmatov, P.D. Burrows, and R.S. Davis
Emerging Roles for FCRL Family Members in Lymphocyte Biology and Disease
Leo C. James
Intracellular antibody immunity and the cytosolic Fc receptor TRIM21
Part II: FcR signaling
Anna Niarakis, Yacine Bounab, Luca Grieco, Roman Roncagalli, Jérôme Garin, Bernard Malissen, Marc Daëron, Denis Thieffry
Computational modeling of the main signaling pathways involved in mast cell activation
Tarik Attout, Andres Floto and Pierre Launay
Calcium channels in FcR signaling
Marcel Kuhny, Carolin N. Zorn, and Michael Huber
Regulation of FceRI signaling by lipid phosphatases
Part III: FcR biology
Marc Daëron
Fc Receptors as Adaptive Immunoreceptors
Jerrard M Hayes, Eoin FJ Cosgrave, Weston B Struwe, Mark Wormald, Gavin P. Davey, Roy Jefferis, Pauline M Rudd
Glycosylation and Fc Receptors
Birgitta Heyman
Antibodies as natural adjuvants
Sanae Ben Mkaddem, Ivy Christou, Elisabetta Rossato, Laureline Berthelot, Agnès Lehuen and Renato C. Monteiro
IgA, IgA receptors and their anti-inflammatory properties
Stylianos Bournazos, David J. DiLillo and Jeffrey V. Ravetch
Humanized mice to study Fc?R function
Dilip K. Challa, Ramraj Velmurugan, Raimund J. Ober and E. Sally Ward
FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions.
Part IV: FcRs and disease
Xinrui Li, Andrew W Gibson and Robert P Kimberly
Human FcR polymorphism and disease.
Hanane el Bannoudi, Andreea Ioan-Facsinay and René E. M. Toes
Bridging auto-antibodies and arthritis; the role of Fc Receptors
P. Mark Hogarth, Jessica C. Anania, Bruce D. Wines
The Fc?R of humans and non-human primates and their interaction with IgG: Implications for induction of inflammation, resistance to infection and the use of therapeutic monoclonal antibodies
Part V: FcRs and therapeutic antibodies
Ann L White, Stephen A Beers and Mark S. Cragg
FcgRIIB as a key determinant of agonistic antibody efficacy
Jantine E. Bakema and Marjolein van Egmond
Fc receptor dependent mechanisms of monoclonal antibody therapy of cancer; professionals at work
Sybille Böhm, Daniela Kao and Falk Nimmerjahn
Sweet and Sour: The role of glycosylation for the anti-inflammatory activity of immunoglobulin G